Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bitwise Crypto Industry Innovators ETF (BITQ) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Bitwise Crypto Industry Innovators ETFTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Bitwise Crypto Industry Innovators ETF vs Regeneron Pharmaceuticals Inc — how do they compare? Bitwise Crypto Industry Innovators ETF trades at $22.36, while Regeneron Pharmaceuticals Inc trades at $796.32 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Bitwise Crypto Industry Innovators ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Bitwise Crypto Industry Innovators ETF nearer its low. Which is the better fit depends on your goals.

BITQREGN
Sector
Crypto-linkedHealth
52-Week High
$30.43$812.27
52-Week Low
$16.74$555.51
Market Cap
$83.19B
Enterprise Value
$77.90B
Dividend Yield
0.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bitwise Crypto Industry Innovators ETF

BITQ trades at $22.88, up 1.42% today, but faces strong technical headwinds with 17 sell signals versus 0 buy signals across moving averages and oscillators. The stock shows bearish momentum with key resistance at $23 and support at $22. Financial metrics remain unavailable in current data, requiring verification through SEC filings.

The technical outlook appears bearish with weak momentum indicators. Investment opportunity depends on upcoming earnings clarity and institutional positioning. Primary risks include market volatility and lack of visible fundamental support until financial disclosures are updated.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.

Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bitwise Crypto Industry Innovators ETF

BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.

Read more on BITQ

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN